Using nanoparticles to improve radiation therapy for prostate cancer
PSMA-targeted AuNPs for MR guided radiotherapy and radiosensitization
This study is looking at a new way to make radiation therapy for prostate cancer work better by using tiny particles that help doctors see the cancer more clearly during treatment and make the cancer cells more responsive to the radiation, which could lead to better results for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Case Western Reserve University NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project ID | NIH-10795016 on NIH RePORTER |
What this research studies
This research focuses on enhancing the effectiveness of radiation therapy for prostate cancer by developing nanoparticles that target prostate-specific membrane antigen (PSMA). These nanoparticles aim to improve the visualization of prostate cancer tissues during MRI-guided radiation therapy, allowing for more precise treatment delivery while minimizing damage to surrounding healthy tissues. Additionally, the nanoparticles are designed to act as radiosensitizers, increasing the cancer cells' sensitivity to radiation. This approach seeks to improve treatment outcomes for patients undergoing radiation therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with prostate cancer who are undergoing radiation therapy.
Not a fit: Patients with non-prostate cancers or those not receiving radiation therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer radiation therapy options for prostate cancer patients.
How similar studies have performed: While there has been limited investigation into targeted radiosensitizers for prostate cancer, the use of nanoparticles in cancer treatment has shown promise in other studies.
Where this research is happening
Cleveland, United States
- Case Western Reserve University — Cleveland, United States (Active)
Researchers
- Principal investigator: Basilion, James Peter — Case Western Reserve University
- Study coordinator: Basilion, James Peter
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.